首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1562491

抗生素市場規模、佔有率、成長分析，按藥物類別、類型、作用機制、地區分類 - 產業預測，2024-2031 年

Antibiotics Market Size, Share, Growth Analysis, By Drug Class, By Type, By Action Mechanism, By Region - Industry Forecast 2024-2031

出版日期: 2024年09月10日 | 出版商:

SkyQuest | 英文 165 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球抗生素市場規模將為506億美元，從2023年的526.7億美元成長到2031年的726.5億美元，預測期（2024-2031）預計複合年成長率為4.10%。

抗生素是一種專門用於對抗細菌感染的抗菌劑。它是用於治療和預防這些感染疾病的一類主要抗生素。感染疾病的傳播和嚴格的政府監管是推動市場的主要因素。此外，抗生素抗藥性感染疾病的增加主要是由於這些藥物的誤用和過度使用，預計處方實踐將轉向細菌感染疾病的新治療方法。根據 CDC 統計，美國每年發生超過 280 萬例抗生素抗藥性感染疾病。此外，腸桿菌科、綠膿桿菌、肺炎克雷伯菌等細菌的抗藥性率很高，接近40%，特別是在開發中國家。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

Pfizer Inc.（US）
GlaxoSmithKline PLC（GSK）（UK）
Sanofi SA（France）
Merck & Co., Inc.（US）
Novartis AG（Switzerland）
Johnson & Johnson（US）
F. Hoffmann-La Roche AG（Switzerland）
AstraZeneca PLC（UK）
Bayer AG（Germany）
Abbott Laboratories（US）
Eli Lilly and Company（US）
Bristol-Myers Squibb Company（US）
Teva Pharmaceutical Industries Ltd.（Israel）
Astellas Pharma Inc.（Japan）
Cipla Ltd（India）
AbbVie, Inc.（US）
Lupin Pharmaceuticals, Inc.（US）
Viatris, Inc.（US）
Melinta Therapeutics LLC（US）
Cipla, Inc.（US）
Shionogi & Co., Ltd.（Japan）
KYORIN Pharmaceutical Co., Ltd.（Japan）
Nabriva Therapeutics PLC（Ireland）

簡介目錄

Product Code: SQMIG35B2164

Global Antibiotics Market size was valued at USD 50.60 billion in 2022 and is poised to grow from USD 52.67 billion in 2023 to USD 72.65 billion by 2031, growing at a CAGR of 4.10% during the forecast period (2024-2031).

Antibiotics are a type of antimicrobial agent specifically designed to combat bacterial infections. They represent the primary class of antibacterial medications used both to treat and prevent such infections. The growing prevalence of infectious diseases and stringent government regulations are key factors driving the market. Additionally, the rise in antibiotic-resistant infections, largely due to misuse or overuse of these drugs, is expected to shift prescription practices towards new treatments for bacterial infections. According to the CDC, there are over 2.8 million cases of antibiotic-resistant infections annually in the U.S. Furthermore, bacteria such as Enterobacteriaceae, Pseudomonas aeruginosa, and Klebsiella pneumoniae exhibit high resistance rates, approaching 40%, particularly in developing countries.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antibiotics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antibiotics Market Segmental Analysis

Global Antibiotics Market is segmented by Drug Class, Type, Action Mechanism, and region. Based on Drug Class, the market is segmented into Cephalosporin, Penicillin, Fluoroquinolone, Macrolides, Carbapenems, Aminoglycosides, Sulfonamides, 7-ACA, and Others. Based on Type, the market is segmented into Branded Antibiotics, Generic Antibiotics. Based on Action Mechanism, the market is segmented into Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, Mycolic Acid Inhibitors, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Antibiotics Market

The increased efforts by pharmaceutical companies to develop new treatments for infectious diseases are expected to significantly drive market growth in the coming years. Supportive government regulations, such as the Increase Act and the Redo Act, are anticipated to facilitate the global approval process for new antibiotics. The introduction of innovative antibiotic drugs is likely to further stimulate market expansion during the forecast period. The growing demand for antibiotics is largely driven by the rising incidence of infectious diseases. The high prevalence of conditions such as lower respiratory infections, pneumonia, malaria, and tuberculosis continues to propel market growth. Collaborations aimed at developing new antibiotics are expected to lead to a surge in the availability of novel drugs. Pharmaceutical companies are working together to innovate and reduce the cost burden associated with drug development. Additionally, increasing public-private partnerships, where funding and innovative R&D approaches are provided by public entities to support antibiotic development, are anticipated to bolster the product pipeline and support market advancement.

Restraints in the Global Antibiotics Market

Antibiotic resistance and lengthy, complex regulatory procedures are expected to impede the growth of the antibiotics market. The challenges posed by antibiotic resistance, coupled with issues related to self-prescription, will also affect the market's trajectory during the forecast period. Additionally, the increasing prevalence of antibiotic resistance and the rising costs associated with drug approval are likely to hinder market expansion. These factors collectively contribute to the anticipated constraints on the growth of the antibiotics market.

Market Trends of the Global Antibiotics Market

According to the CDC, antibiotic-resistant infections affect over 2.8 million people in the U.S. annually. In developing countries, certain bacteria such as Enterobacteriaceae, P. aeruginosa, and K. pneumoniae exhibit a high resistance rate, reaching around 40%. This growing resistance poses a significant challenge in managing bacterial infections, particularly in regions with limited healthcare infrastructure. The rise in antibiotic-resistant strains underscores the urgent need for new treatment options and stricter antibiotic usage guidelines to combat the spread of these resilient pathogens.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Pricing Analysis
Value Chain Analysis
Ecosystem of the Market
Trade Analysis
Supply chain Analysis
Case study Analysis
Patent Analysis
Customer & Buying Criteria Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
PESTEL Analysis
Degree of Competition

Antibiotics Market by Drug Class

Market Overview
Cephalosporin
Penicillin
Fluoroquinolone
Macrolides
Carbapenems
Aminoglycosides
Sulfonamides
7-ACA
Others

Antibiotics Market by Type

Market Overview
Branded Antibiotics
Generic Antibiotics

Antibiotics Market by Action Mechanism

Market Overview
Cell Wall Synthesis Inhibitors
Protein Synthesis Inhibitors
DNA Synthesis Inhibitors
RNA Synthesis Inhibitors
Mycolic Acid Inhibitors
Others

Antibiotics Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline PLC (GSK) (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Ltd (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Melinta Therapeutics LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shionogi & Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
KYORIN Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nabriva Therapeutics PLC (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments